Delivery Order SPE2DB22D1106-SPE2DB25FFHG4
- Not listed
- The Defense Logistics Agency has awarded a delivery order valued at $40,155.43 to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/ml pen injectors, with an ultimate completion date of September 3, 2025. This competitively awarded, firm fixed-price contract represents a non-set-aside transaction executed on September 2, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, with extensive experience...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $33,797.51 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 mg/ml pen injectors. This competitive award, issued on July 22, 2025, with an ultimate completion date of July 23, 2025, represents a firm fixed-price delivery order with no set-aside designation. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,830.00 to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/mL pen injectors on June 2, 2025, with completion expected by June 3, 2025. This firm fixed-price delivery order represents a non-competitive award issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.99 million and extending through December 2026. SKYRIZI is a biologic immunosuppressant used to...
- The Defense Logistics Agency awarded a delivery order valued at $67,658.42 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 mg/ml pen injectors. This firm fixed-price, non-set-aside contract was awarded on September 11, 2025, with an ultimate completion date of September 12, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. SKYRIZI is a prescription biologic medication used to treat inflammatory skin conditions, representing...
- The Defense Logistics Agency awarded a delivery order valued at $78,225.51 to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of SKYRIZI 150 mg/ml pen injectors. This firm fixed-price, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion comprehensive pharmaceutical supply vehicle running through December 2026. The place of performance is listed as...
- The Defense Logistics Agency awarded a delivery order valued at $21,568.25 to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/mL pen injectors on August 28, 2025. This firm fixed-price, non-set-aside contract represents a single delivery transaction under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August...
- The Defense Logistics Agency awarded a delivery order valued at $15,904.96 to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/mL pen injectors. This firm fixed price, non-competitive delivery order was issued on July 29, 2025, with an ultimate completion date of July 30, 2025. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. SKYRIZI is a prescription biologic medication used to treat...
- The Defense Logistics Agency awarded a $25,899.93 firm fixed price delivery order to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/mL pen injectors, with an ultimate completion date of July 14, 2025. This competitively awarded, non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The delivery location is AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $48,881.85 to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/mL pen injectors under a firm fixed-price contract type. The award, issued on August 28, 2025, with an ultimate completion date of August 29, 2025, represents a non-competitive delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location. SKYRIZI is a...
- The Defense Logistics Agency awarded a $38,911.60 delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of SKYRIZI 150 mg/ml pen injectors. This firm fixed price, non-set-aside contract will be completed by August 27, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FFHG4Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $64,305.29 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 mg/mL pen injectors. This firm fixed-price delivery order, awarded September 5, 2025, with completion targeted for September 8, 2025, will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's capability to compete in open federal procurement for pharmaceutical products. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. As a prime pharmaceutical vendor to the Defense Logistics Agency, AmerisourceBergen supplies a comprehensive range of medications and medical supplies to support military healthcare systems worldwide. SKYRIZI, a biologic immunosuppressant used primarily to treat inflammatory conditions, represents one of the specialized pharmaceutical products the company delivers through its federal contract portfolio. The DLA's reliance on AmerisourceBergen for such medical commodities underscores the vendor's critical role in supporting Defense Health Agency operations and broader federal healthcare procurement initiatives.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $64.3k | 9/5/25 |